Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
Condition: Non-small Cell Lung Cancer Interventions: Biological: pembrolizumab; Drug: carboplatin; Drug: paclitaxel; Drug: pemetrexed Sponsor: Merck Sharp & Dohme Corp. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | China Health | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study